Abcodia | detecting cancer earlier
detecting cancer earlier


Despite advances in diagnosis and treatment, cancer remains a highly lethal disease with as many as 14.2 million new cancer cases and 8.2 million deaths reported annually worldwide. Research shows that the earlier cancer can be detected, the better the survival prospects. However, few tests can accurately detect cancer before symptoms appear.

Abcodia, together with our partners and collaborators, are engaged in the clinical and commercial development of novel, scientifically validated tests for the early detection of several cancers. In 2013 Abcodia formed an alliance with Cancer Research UK to discover and validate blood-based biomarkers that may be used in the earlier detection of pancreatic, lung, colorectal and oesophageal cancers. more...


Abcodia's first product, the ROCA® Test, determines the likelihood of a woman having having ovarian cancer - even before symptoms appear. In clinical studies of patients in the general population, the ROCA Test along with appropriate clinical follow up, has been shown to detect more than twice as many ovarian cancers as tests that use a fixed CA125 cutoff.

The ROCA Test is CE marked and is available in the private healthcare market in the U.K. and is available in select U.S. markets. For more information about the most proven method of monitoring a womann's risk of having ovarian cancer, visit or



Between 2001 and 2005 202,638 women volunteers were enrolled into the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Volunteers donated serum samples for up to 10 years. The resulting biobank contains over 5 million straws of serum representing all diseases. These prospective longitudinal samples are rare and ideal for use in the development of biomarkers for the earlier detection of disease.

Abcodia has the exclusive commercial rights to this biobank and uses these samples for internal research and development and provides samples under license for use in the third party projects.


Abcodia Statement on the ROCA® Test for Ovarian Cancer Screening

Abcodia acknowledges the recent statement issued by the U.S. Food and Drug Administration (FDA) regarding the use of blood tests for ovarian cancer screening. Notwithstanding our confidence in the clinical utility of the ROCA® Test, we are voluntarily choosing to temporarily suspend its commercial availability in the United States and the United Kingdom. More on the US Statement...

More on the UK Statement...

Abcodia's ROCA® Test used in UKCTOCS trial; data shows ovarian cancer screening could reduce mortality by 20%

Data published in The Lancet today by one of the largest ever randomised trials has concluded that ovarian cancer screening may reduce ovarian cancer mortality by an estimated 20% after follow up of up to 14 years. Longer follow-up is needed to determine the ultimate mortality reduction and if screening the general population is cost effective. More...